Compare INSM & PSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | PSA |
|---|---|---|
| Founded | 1988 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 48.8B |
| IPO Year | 2000 | N/A |
| Metric | INSM | PSA |
|---|---|---|
| Price | $156.37 | $282.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 23 | 13 |
| Target Price | $188.71 | ★ $314.23 |
| AVG Volume (30 Days) | ★ 2.6M | 1.2M |
| Earning Date | 02-19-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 4.25% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.63 |
| Revenue | $447,022,000.00 | ★ $4,795,182,000.00 |
| Revenue This Year | $49.51 | $1.73 |
| Revenue Next Year | $134.47 | $3.15 |
| P/E Ratio | ★ N/A | $29.35 |
| Revenue Growth | ★ 30.34 | 2.06 |
| 52 Week Low | $60.40 | $256.54 |
| 52 Week High | $212.75 | $322.49 |
| Indicator | INSM | PSA |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 56.30 |
| Support Level | $153.19 | $283.50 |
| Resistance Level | $164.62 | $291.76 |
| Average True Range (ATR) | 7.67 | 7.46 |
| MACD | -0.76 | 1.53 |
| Stochastic Oscillator | 9.60 | 67.36 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Public Storage is the largest owner of self-storage facilities in the US, with more than 3,300 self-storage facilities in 40 states and approximately 245 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.